This DOX nanoformulation exploits the tumor targeting specificity of HFn nanocage, as a result of the specific binding between HFn and the transferrin receptor 1 (TfR1), which is overexpressed in cancers9,20. This evidence concerns the gene TFRC and neoplasm.